MarketWatch

(PMZN) SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...
EurekAlert!

Blood test to detect alpha-synuclein protein could revolutionize Parkinson's disease diagnostics

Amsterdam, July 22, 2024 – To date Parkinson's disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker ...

Potential new target to treat Parkinson's disease discovered

About 1 million Americans suffer from Parkinson's disease, with around 90,000 new cases diagnosed each year, according to the ...
Seeking Alpha

CND Life Sciences' Syn-One Test® Detects Alpha-Synuclein in Skin Biopsies of Patients with REM Sleep Behavior Disorder

Data from the Syn-Sleep Study shows the Syn-One Test detected phosphorylated alpha-synuclein in skin biopsies of 75% of patients with iRBD at baseline This NIH-sponsored, multicenter, prospective ...
Nasdaq

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to ...

“These are the first data to link ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in neurons of Parkinson’s disease patients,” said Stephen C. Glover, ZyVersa’s ...
TMCnet

SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a ...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...